Sosei Group buys Heptares Therapeutics for $400 mln
Sosei Group Corp. said late Sunday that it has acquired Heptares Therapeutics Ltd for about $400 million. The deal include $180 million cash while another $220 million is contingent upon the successful progression of the company’s pipeline and platform. Welwyn Garden City, U.K.-based Heptares is reportedly developing an experimental drug to treat Alzheimer's disease that is in early stage clinical testing, according to Bloomberg News. Heptares investors include MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund, Takeda Ventures and the Stanley Family Foundation. Moelis & Company UK LLP advised Sosei while Goldman Sachs provided financial advice to Heptares.
23 February 2015•9 mins read
